Bristol-Myers Squibb Company and bluebird bio have managed to get their B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) therapy idecabtagene vicleucel in to the US Food and Drug Administration with a fighting chance at making the deadline for a contingent value right (CVR) payout that Bristol owes Celgene Corporation shareholders under the companies’ 2019 merger agreement.
Bristol and bluebird announced 22 September that the FDA accepted their biologic license application (BLA) for idecabtagene vicleucel (ide-cel, formerly bb2121) in the fourth-line or later treatment of multiple myeloma for priority review – which
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?